Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P.

Rhea-AI Summary

Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast will be available under the Events & Presentations section on the company’s Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

Argus Jan 8 session

-4.34% close to close Open Argus

Details

News Market Reaction – ANNX

On Jan 8, the first trading day after this news, ANNX closed 4.34% below the previous close.

Data tracked by StockTitan Argus for the Jan 8 session.

Market Context

This announcement highlights Annexon’s planned presentation at a major healthcare conference, offeri...

Analysis

This announcement highlights Annexon’s planned presentation at a major healthcare conference, offering management another forum to discuss its neuroinflammatory disease platform that targets nearly 10 million affected patients. In recent months, the company strengthened its balance sheet through public offerings and reported Q3 2025 results with cash of $188.7M and projected runway into late Q1 2027. Investors may watch for any new clinical or strategic details shared in the presentation and subsequent webcasts.

Key Figures

Patients impacted: nearly 10 million people Conference edition: 44th Annual Presentation time: Jan 14, 2026, 11:15 a.m. PST +1 more

Patients impacted

nearly 10 million people

Neuroinflammatory diseases targeted by company platform

Conference edition

44th Annual

J.P. Morgan Healthcare Conference

Presentation time

Jan 14, 2026, 11:15 a.m. PST

Company presentation slot at JPM Healthcare Conference

Webcast availability

30 days

Replay duration for conference webcast on company website

Historical Context

5 past events · Latest: Dec 16

5 events

1. Dec 16

   Inducement grant

   24h Move

   +2.1%

   New employee stock option grant under inducement plan.

2. Nov 14

   Offering closing

   24h Move

   +11.4%

   Closed equity offering with full underwriter option exercise.

3. Nov 12

   Offering pricing

   24h Move

   -4.4%

   Priced public offering of stock and pre-funded warrants.

4. Nov 12

   Offering announcement

   24h Move

   -4.4%

   Announced proposed $75M equity and warrant offering.

5. Nov 10

   Earnings & pipeline

   24h Move

   -0.3%

   Q3 2025 results and late-stage pipeline/milestone update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunotherapies, neuroinflammatory

2 terms

immunotherapies medical

"advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

neuroinflammatory medical

"targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people"

Neuroinflammatory describes inflammation occurring in the brain, spinal cord or peripheral nerves when the body's immune response becomes active in nervous tissue. For investors, it matters because neuroinflammatory processes are central to many neurological diseases and can drive demand for new drugs, affect clinical trial outcomes, and influence regulatory decisions—similar to how a neighborhood dispute can change local services and property values, inflammation can reshape treatment needs and company prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Annexon (ANNX) present at the J.P. Morgan Healthcare Conference?

Annexon will present on January 14, 2026 at 11:15 a.m. PST.

How can investors watch Annexon (ANNX) live at the J.P. Morgan presentation?

A live webcast will be available under Events & Presentations on the Annexon investor website at www.annexonbio.com.

Will Annexon (ANNX) provide a replay of the J.P. Morgan presentation and for how long?

Yes. A replay will be archived on the Annexon website for 30 days after the presentation.

Who from Annexon (ANNX) will present at the J.P. Morgan Healthcare Conference?

Douglas Love, president and chief executive officer, will present.

Does Annexon (ANNX) announcement list the presentation topics or slides?

The announcement does not specify presentation topics or whether slides will be posted.